Pathogenesis of cardiomyopathy
US6201168A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 20, 1999 |
| Grant date | Mar 13, 2001 |
| Priority date | — |
| Expiry date | Aug 20, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a mouse, cells derived therefrom, and methods for using the mouse, the mouse being homozygous for a disrupted .delta.-sarcoglycan gene, the disruption in the gene having been introduced into the mouse or an ancestor of the mouse at an embryonic stage. The disruption prevents the synthesis of functional .delta.-sarcoglycan in cells of the mouse and results in the mouse having a reduced amount of .beta.- and .epsilon.-sarcoglycan and sarcospan, and a disruption of the sarcoglycan-sarcospan complex in smooth muscle of the mouse. Also disclosed is a mouse, cells derived therefrom, and methods for using the mouse, the mouse being homozygous for a disrupted .beta.-sarcoglycan gene, the disruption in the gene having been introduced into the mouse or an ancestor of the mouse at an embryonic stage. The disruption prevents the synthesis of functional .beta.-sarcoglycan in cells of the mouse and results in the mouse having a reduced amount of .delta.-and .epsilon.-sarcoglycan and sarcospan and .alpha.-dystroglycan in smooth muscle of the mouse.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.